Form 4: Noubar Afeyan, Moderna Director, Sells Shares Under 10b5-1 Trading Plan

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on March 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 27, 2024, Noubar Afeyan, a director of Moderna, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on February 27, 2023, and amended on November 7, 2023.
• The transactions involved multiple sales at varying prices, ranging from $105.19 to $110.97 per share.
• A total of 14,900 shares were sold directly.
• Following the reported transactions, Afeyan directly owns 2,101,931 shares of Moderna common stock.
• Afeyan also has indirect ownership through Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing simply reports a pre-planned sale of shares by a director, which is a routine event. There's no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of trading on material non-public information. The market typically analyzes the size and frequency of such sales to gauge insider sentiment.

Comparison to Industry Standards

• Comparing Afeyan's transactions to other directors in similar biotech companies, the volume of shares sold is relatively moderate.
• For example, directors at companies like BioNTech or Pfizer often execute similar sales under 10b5-1 plans, with the size of the transactions varying based on their holdings and personal financial strategies.
• The weighted average prices achieved are within the typical trading range for MRNA during the period, indicating no unusual pricing.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder sentiment, but given the pre-planned nature of the transaction, the impact is likely to be minimal.
• Employees and other stakeholders are unlikely to be significantly affected by this transaction.

Key Dates